Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586293 | 0.86 | PTGER1 (0.32) | EPHX1POLB | |
| SCHEMBL14586324 | 0.81 | EPHX1 (0.31) | EPHX1POLB | |
| SCHEMBL132657 | 0.79 | DGAT1 (0.42) | MEN1KMT2ADGAT1 | |
| SCHEMBL23867400 | 0.77 | KDM4E (0.32) | DGAT1 | |
| Ammonia Solution, Strong SCHEMBL9998482 | 0.77 | DGAT1 (0.41) | MEN1KMT2ADGAT1 | |
| SCHEMBL19139139 | 0.77 | EPHX1 (0.34) | EPHX1POLBMEN1KMT2ADGAT1 | |
| SCHEMBL24019746 | 0.75 | EPHX1 (0.33) | EPHX1POLBMEN1KMT2ADGAT1 | |
| SCHEMBL1289839 | 0.74 | — | — | |
| SCHEMBL14586323 | 0.73 | EPHX1 (0.37) | EPHX1POLBMEN1KMT2A | |
| SCHEMBL22001990 | 0.73 | GAA (0.33) | EPHX1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188524-A1 | MOLECULAR LOGIC GATES FOR CONTROLLED MATERIAL DEGRADATION | UNIVERSITY OF WASHINGTON | 2020-06-18 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | EPHX1 2260/4885POLB 1396/4885MEN1 1427/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | EPHX1 2260/4885POLB 1396/4885MEN1 1427/4885 |
| US-20200188524-A1 | MOLECULAR LOGIC GATES FOR CONTROLLED MATERIAL DEGRADATION | LIG4, LIG1, PCNA | EPHX1 1037/4885POLB 273/4885MEN1 620/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | EPHX1 2260/4885POLB 1396/4885MEN1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.